{
    "ticker": "NTRA",
    "name": "Natera, Inc.",
    "description": "Natera, Inc. is a global leader in genetic testing and diagnostics, dedicated to advancing the field of genomics and improving patient care through innovative technology. Founded in 2004, Natera specializes in non-invasive prenatal testing (NIPT), reproductive health, and oncology. The company\u2019s flagship product, Panorama, is one of the most accurate NIPT solutions available, enabling expectant parents to assess the risk of certain genetic conditions in their fetus. Natera also offers tests for miscarriage analysis, carrier screening, and cancer diagnostics, leveraging its proprietary technology to provide comprehensive insights into genetic health. With a strong emphasis on research and development, Natera is committed to expanding its product offerings and enhancing its testing capabilities. The company aims to empower patients and healthcare providers with actionable genetic information to guide critical medical decisions. Natera\u2019s mission is centered around the belief that genomic information has the potential to transform healthcare and improve patient outcomes worldwide. Through collaborations with healthcare professionals and institutions, Natera continues to drive innovation in genetic testing and personalized medicine.",
    "industry": [
        "Healthcare",
        "Genetics"
    ],
    "headquarters": "San Carlos, California, USA",
    "founded": "2004",
    "website": "https://www.natera.com",
    "ceo": "Steve Chapman",
    "social_media": {
        "twitter": "https://twitter.com/Natera",
        "linkedin": "https://www.linkedin.com/company/natera/"
    },
    "investor_relations": "https://investors.natera.com",
    "key_executives": [
        {
            "name": "Steve Chapman",
            "position": "CEO"
        },
        {
            "name": "Michael Brophy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Prenatal Testing",
            "products": [
                "Panorama"
            ]
        },
        {
            "category": "Oncology Testing",
            "products": [
                "Signatera"
            ]
        },
        {
            "category": "Reproductive Health",
            "products": [
                "Carrier Screening"
            ]
        }
    ],
    "seo": {
        "meta_title": "Natera, Inc. | Genetic Testing and Diagnostics",
        "meta_description": "Explore Natera, Inc., a leader in genetic testing and diagnostics, specializing in non-invasive prenatal testing, oncology, and reproductive health.",
        "keywords": [
            "Natera",
            "Genetic Testing",
            "Prenatal Testing",
            "Oncology",
            "Personalized Medicine"
        ]
    },
    "faq": [
        {
            "question": "What does Natera specialize in?",
            "answer": "Natera specializes in genetic testing and diagnostics, including non-invasive prenatal testing and oncology."
        },
        {
            "question": "Who is the CEO of Natera?",
            "answer": "Steve Chapman is the CEO of Natera, Inc."
        },
        {
            "question": "Where is Natera headquartered?",
            "answer": "Natera is headquartered in San Carlos, California, USA."
        },
        {
            "question": "What are Natera's main products?",
            "answer": "Natera's main products include Panorama for prenatal testing, Signatera for oncology, and carrier screening tests."
        },
        {
            "question": "When was Natera founded?",
            "answer": "Natera was founded in 2004."
        }
    ],
    "competitors": [
        "NIPT",
        "MYGN",
        "ILMN"
    ],
    "related_stocks": [
        "SGEN",
        "HOLX",
        "CDNA",
        "AMGN"
    ]
}